

FY26 interim results presentation

11 November 2025

Richard Tyson, CEO

Paul Fry, CFO



Proactive response to H1 disruption and strong strategic progress

Strong strategic execution laying foundation for future growth and margin expansion

Proactive response to Q1 disruption in Imaging & Analysis: tariffs recovered, manufacturing adjustments; orders recovery in Q2

25% order growth in Advanced Technologies as commercial customer strategy takes hold

New products reinforce our technology leadership in our structural growth markets


Strong balance sheet, share buyback programme to be extended by £50m to £100m total

Tariffs and academic funding impact in Q1

Tariffs: direct impacts successfully mitigated; open order book repriced, customer uncertainty

Academic funding: US academic customer orders delayed by proposed funding cuts

US federal funding



An improving picture from Q2 with order momentum

Tariffs: adjusted manufacturing locations; rare earth challenge addressed through engineering innovation and sourcing

Academic funding: US federal funding normalising; cuts expected to be largely reversed; Exploring new funding sources and commercial customer base

Financial review

Paul Fry
CFO

FY26 Interim results

11 November 2025




Challenging H1 following global disruption; well positioned well for strong H2

£'m	H1 FY26	H1 FY25	% Growth	% OCC ¹
Order intake	205.2	204.9	+0.1%	+1.4%
Revenue	185.5	204.3	(9.2%)	(7.9%)
Gross margin	55.0%	55.4%	(40bps)	(20bps)
Adjusted operating profit	24.7	35.3	(30.0%)	(22.9%)
Adjusted operating margin	13.3%	17.3%	(400bps)	(280bps)
R&D expense % revenue	9.3%	9.3%		
Normalised cash conversion ²	41%	44%		
Free Cash Flow ³	0.2	(7.1)		
Adjusted EPS basic	33.0p	46.6p		(29.2%)
Interim dividend	5.4p	5.1p		+5.9%

- All financials presented for **continuing operations** (NanoScience classified as held for sale)
- Market turbulence beginning in Q4 FY25, accelerating in Q1 FY26 with new tariff policies, impacting order intake
- **Imaging & Analysis** division revenue most impacted by subdued order intake, with Belfast business most exposed
- **Advanced Technologies** order intake growing strongly, with accelerating order book yet to fully pull through to revenue, and shift towards larger, longer lead time systems
- **Gross margin consistent and overheads flat** versus H1 FY25
- **High operational leverage** leading to sharp drop through from revenue to Adjusted Operating Profit (AOP) and cash

¹Organic constant currency ²Normalised excludes Severn Beach investment and Yatton proceeds ³Free cash flow before acquisitions or other corporate development


Revenue (£'m)




- H1 revenue impacted by Q1 tariff related shipping delays and disrupted order intake
- **I&A** division OCC¹ decline of 8.5% driven by:
 - Broader **customer hesitancy** in converting opportunities to orders
 - Continued headwinds in healthcare and life sciences (-9.1%)
- **Advanced Technologies** division OCC decline of 6.2% driven by:
 - Some impact of timing delays to Q2 shipments
 - Consistently high order intake growth from Q4 FY25 yet to fully show up in revenue
 - Semiconductor **orderbook transition**:
 - Towards **larger, multi-chamber, commercial** customers mainly US and Europe
 - Leading to **higher average selling prices (ASP), longer lead times**
 - Early teens **growth expected H2**

¹ Organic constant currency, reflecting acquisition of FemtoTools from June 2024.

Order intake (£'m)




Revenue (£'m)




Book to Bill = 1.06

H1 order intake by end customer type




¹All growth rates shown OCC

Order intake (£'m)




Revenue (£'m)



Book to Bill = 1.25


H1 order intake by end customer type



¹All growth rates shown OCC

Adjusted operating profit evolution

- Group gross margin consistent at 55% OCC, through tariff re-pricing, operational efficiency and higher plasma ASPs
- Total absolute overheads marginally lower than H1 FY25, but ~280 bps higher as % of OCC revenue
- AOP margin decline direct result of revenue decline and FX headwind



	H1 FY26 AOP	H1 FY26 OCC Margin %	H1 FY26 Margin %	H1 FY25 Margin %
Imaging & Analysis	£23.7m	18.4%	17.1%	22.5%
Advanced Technologies	£1.0m	2.5%	2.1%	1.4%
OI Group	£24.7m	14.5%	13.3%	17.3%


Adjustments to statutory results

£'m	H1 FY26	H1 FY25	% Growth	% OCC ¹
Adjusted operating profit	24.7	35.3	(30.0%)	(22.9%)
Net Finance Income	0.7	0.7		
Adjusted profit before tax	25.4	36.0	(29.4%)	(22.5%)
Amortisation and impairment of acquired intangible assets	(4.2)	(4.7)		
Non-recurring items ¹	(2.1)	(0.7)		
Mark-to-market of currency hedges ²	1.2	2.7		
Statutory profit before tax	20.3	33.3	(39.0%)	
Taxation	(5.2)	(7.9)		
Statutory profit after tax from continuing operations	15.1	25.4	(40.6%)	
Profit/(loss) from discontinued operations	(3.1)	(1.3)		
Profit/(loss) for the period	12.0	24.1		

- **No changes to definitions of adjusting items**
- Non-recurring items include:
 - Belfast restructuring costs (£2.0m)
 - Plasma relocation costs (£2.8m)
 - Profit on disposal of Yatton site of +£3.7m
- Normalised effective **adjusted tax rate** expected to be ~24.8% for full year
- **Discontinued operations** comprises all post-tax revenues and costs directly related to the NanoScience business, including transaction related costs
- NanoScience adjusted loss of £2.2m in H1

¹Non-recurring items include a non-cash charge of £0.6m against the unwind of discount on FemtoTools contingent consideration which is recognised as financial expenditure. ²Changes in valuation of hedging instruments

Cash flow – improved FCF versus H1 prior year; accelerating into FY27



Working capital profile reflects:

- Inventories - finished goods shipments and materials build for H2 acceleration
- Other - typical H1 profile; down £7m (11%) versus H1 PY
- **Expecting strong FY27 cash generation:**
 - **Capital expenditure** reducing post-Severn Beach, normalising to £8m-£10m pa
 - **Non-recurring** costs completing (FY26 £7m-£8m; FY27 not material)
 - **Pension payments** ceased as at end October (FY26 £5.25m; FY27 nil)
- **H1 closing net cash £45.1m**
 - **Share buyback** of £25.5m and dividend payment of £9.9m in H1
 - NanoScience **sale proceeds**² expected H2

¹ Capex includes proceeds of £4.8m from Yatton sale ²Gross proceeds of £57m. Tax due on proceeds expected to be ~£4m, of which £3m expected to be paid in H2

Organic investment

Driving growth and margin

E.g.

- R&D at 8%-9% of revenue
- Severn Beach; Regional build out

Dividends

Progressive, in line with underlying earnings

- FY24: 20.8p +6.7%
- FY25: 22.2p +6.7%
- **H1 FY26 5.4p +5.9%**

Inorganic

Compelling strategic and synergy case, exceeding returns hurdles

Priorities
for excess
cash

Share buybacks

Compelling case to create value for our individual shareholders

Current share buyback programme to be extended by a further £50m, to £100m¹

¹ As at 31 October 2025 £31.9m of the buyback programme has been completed

For continuing operations (excl. NanoScience):


Revenue

- I&A OCC H2 revenue flat on prior year, supported by Q2 orders flat on prior year
- AT OCC H2 revenue growing mid-teens – full order book for the year
- H2 FX headwind of ~£5m (FY ~£9m)
- Macro and tariff uncertainties remain

Adjusted operating profit (AOP)

- Operation leverage benefit from AT growth in H2
- Belfast related savings of ~£4m in H2 versus prior year¹
- H2 projected FX headwind ~£3m (FY ~£5.5m)²
- Full year OCC AOP expected to be broadly in line with prior year

AOP growth drivers versus H2 prior year (£'m)



¹Full year impact versus FY25 expected to be ~£5-6m ²Overseas earnings USD dominated. Assuming GBP:USD rate 1.34. A USD 1 cent movement = ~£0.2m operating profit impact

Strong progress on strategic actions

Richard Tyson
CEO

FY26 Interim results

11 November 2025



Imaging & Analysis

Leading range of microscopy, scientific cameras, spectroscopy and associated analytical tools and software











H1 FY26

Orders	Revenue	Margin
£146.6m	£138.9m	17.1%

Medium-term target

Revenue	Margin
4-6%+ CAGR	22-24%

- Short-term demand impacts in core markets; medium-term prospects remain exciting
- Q1 orders impacted by global trading environment; Q2 in line with prior year, demand stabilising
- Agile and customer-focused response to tariffs: order book repriced, footprint adjustments complete in H2
- Material positive impact on H2 margin expected from self-help actions in Belfast as well as usual seasonality



Positioned in structurally growing markets

	Medium-term CAGR **	% of divisional revenue	% change in revenue YOY	
 Materials Analysis	4-7%	55%	(7%)	Expanded product range driving increased market penetration; continued sustainable growth expected
 Semiconductors	6-9%	16%	(10%)	Expanding product manufacturing lines across US, Europe and Asia; applications across lifecycle
 Healthcare & Life Science	8-12%	22%	(9%)	Market remains weak but steady; positive book-to-bill; order growth in US and rebuilding OEM portfolio

Globally diversified

- Globally diversified business, opportunity in all regions.
- US weighting increasing with resilient growth in H1 and as China reduces to c.20%
- Medium term demand drivers remain strong across all markets driven by technology
- Positive book-to-bill in life science
- Investment to localise key infrastructure and supply chains supports larger opportunity pipelines

* Other markets, including quantum and fundamental science, constitute remaining 7% of divisional revenue (£10m, -1%). Orders in other markets were up 66% CC, primarily driven by quantum **16**


**Market growth opportunities refer to applied R&D and production and testing; Source: SDi/Gartner

Made in China: protecting market share, creating opportunity

China for China strategy:
New electron microscopy
detector assembly



Made in Germany: dual AFM production in US and Germany



Ulm site building atomic force
microscopes for customers in
China and Europe

Adapted footprint brings **greater flexibility** for
customers and **Oxford Instruments**

Spotlight on USA: a good performance in an unpredictable environment

Orders **+11% CC**

- Strong recovery from disrupted Q1
- Growth underpinned by commercial customers
- Strong pipeline and focus on new and expanded sources of funding
- Service revenue up 9% year on year

Comprehensive set of actions taken to improve business performance and returns



Rightsizing of workforce:
20% reduction
completed
in H1



Operational programme
improving lead times,
product quality, and
productivity



Focus on rebuilding
relationships driving
growth in OEM orders
and pipeline



Product line restructure
and launches targeting
increased margin and
market share

Tangible outcomes include:

Benefit of c.**£4m** cost base
reduction to flow through in H2

Inventory reduction:
£4m vs **£2.5m** target

60% productivity gain

Simpler interfaces, faster results, improved capabilities

Budget-friendly atomic force microscope extends customer reach and margin



Simpler interface: no need to be an expert to generate high-quality images

Nuclear magnetic resonance technology leadership secured with two launches in 2025



New X-Pulse 90 benchtop instrument

New NMR instrument installed at GSK pre-launch for pharma packaging




Scientific camera innovation unlocking new capabilities for Oxford



First products launched from First Light Imaging: high speed and UV editions

Applications include semiconductor life science, quantum and astronomy



New Raman system enables greater speed and flexibility than ever



Improved light transmission and automation

Maintaining leadership through continued R&D investment at target levels of 8-9% of revenue

Advanced Technologies

Compound semiconductor fabrication equipment and X-ray technology


H1 FY26

Orders	Revenue	Margin
£58.6m	£46.6m	2.1%

Medium-term target

Revenue	Margin
10%+ CAGR	10-12%

- Strong positive momentum in compound semiconductor business driven by commercial customers
- Full order book to support another year of strong growth and margin improvement
- New site fully operational with new clean room supporting increased volume of customer demonstrations; capacity to scale as revenue grows
- Double digit market growth supporting exciting opportunity



State-of-the art facility and focus on commercial sector underpin strong order growth

Leading expertise in **fabrication and process development** positions us to access **10%+ market growth** in compound semiconductor

25% order growth underpinned by **growth in commercial customers**

Full order book for FY26 supports confidence in full year **revenue growth** and **margin enhancement**

World class **clean room** fully installed and operational; new site capacity provides scope to double revenue

Tier 1 European and US **commercial customers** **investing** in datacentres, AI and AR

New site and product streamlining increasing productivity: **12% labour efficiency** uplift YTD

Specialist expertise in critical layer applications for AI, datacentres, quantum and augmented reality **attracting major technology players** and **boosting average system price**

Enabling
today's
hyperscale
datacentres



Providing solutions
for fabrication of
opto (laser) devices
for next gen data
transfer rates

Supporting
tomorrow's
datacentre
developments



Developing
gallium nitride
applications for
reduced power
consumption

Playing a key
role in quantum
technology
transition




Supporting qubit
fabrication,
quantum sensing
and
communications

Accelerating
augmented
reality
roadmaps



Active in
developing
multiple elements
of augmented
reality glasses
(see right)



**Accelerating development of
augmented reality applications with
global technology companies**

- Imaging & Analysis self-help driving cost efficiencies and maintaining gross margin
- Strong double digit order growth expanding reach into commercial customers in Advanced Technologies
- Continuing progress on operational excellence programme, now expanding to our other UK sites
- 9.3% revenue invested in R&D with range of products launched this year
- Sale of NanoScience supports improved margin and ROCE
- Cash conversion expected to return to target levels
- Strong balance sheet, and current share buyback programme to be extended by a further £50m to £100m



Proactive response to Q1 disruption; stronger H2 expected

Stronger H2 expected as benefits of actions taken flow through to revenue, profit and margin

Compound semiconductor strategy delivering strong order growth from commercial customers

Strong balance sheet, and share buyback extended

Strong strategic execution laying foundation for future growth and margin expansion





Q&A



Appendix

Full Year FY25 pro-forma (unaudited)

Pro-Forma (unaudited)	Full year to 31 March 2025		
	Adjusted £m	Adjusting items £m	Total £m
Revenue	443.4	-	443.4
Cost of sales	(199.1)	-	(199.1)
Gross profit	244.3	-	244.3
Research and development	(38.7)	-	(38.7)
Selling and marketing	(73.3)	-	(73.3)
Administration and shared services	(53.7)	(41.6)	(95.3)
Foreign exchange gain/(loss)	0.9	(0.3)	0.6
Operating profit	79.5	(41.9)	37.6
Financial Income	2.6	-	2.6
Financial expenditure	(1.4)	(0.6)	(2.0)
Profit/(loss) before income tax	80.7	(42.5)	38.2
Income tax (expense)/credit	(17.4)	4.2	(13.2)
Profit/(loss) for the period from continuing operations	63.3	(38.3)	25.0
Profit/(loss) from discontinued operations after tax	1.9	(0.9)	1.0
Profit/(loss) for the year attributable to shareholders	65.2	(39.2)	26.0
Basic earnings per share (in pence)			
Continuing operations	109.1		43.1
From profit for the year (incl. discontinued operations)	112.4		44.8
Diluted earnings per share (in pence)			
Continuing operations	107.8		42.6
From profit for the year (incl. discontinued operations)	111.1		44.3

Full year to 31 March 2025			
£m	Imaging & Analysis	Advanced Techn- ologies	Total
Revenue	330.5	112.9	443.4
Adjusted operating profit	73.9	5.6	79.5
Adjusted operating margin	22.4%	5.0%	17.9%